Seeking Alpha
 

Actavis plc. (ACT)

- NYSE
  • Apr. 26, 2012, 1:20 PM
    Watson Pharmaceuticals (WPI +6.6%) gets a lift today after agreeing to acquire Swiss rival Actavis. The purchase gives the company a boost in the global rankings of generic drug makers to the number 3 spot. Citigroup upgrades the stock to Buy on the news.
    | Comment!
  • Apr. 26, 2012, 9:20 AM
    Premarket gainers: PATK +26%. HTWR +15%. REGN +14%. NUAN +14%. LOGI +14%. VHC +12%. CTXS +12%. NRGY +10%. EQIX +9%. CRUS +8%. SPPI +8%. INCY +7%. XLNX +7%. WPI +7%. AMRN +5%. EA +7%. MWW +5%. AH +6%. PHM +6%. AIS +5%. AIXG +5%. LSI +4%. TS +3%. UN +3%. ZNGA +3%. FRO +3%. RDS +3%.
    Losers: FURX -28%. PCS -15%. HRB -15%. TQNT -14%. ALU -13%. TSPT -12%. AET -9%. PTX -7%. AKAM -6%. AZN -6%. ZMH -5%. DB -5%. HERO -5%. STD -5%. DOW -4%. CELG -4%. CS -4%. CROX -4%. GG -3%. BWA -3%. UNH -3%. LVS -3%. VALE -3%. UPS -3%. POT -3%.
    | Comment!
  • Apr. 25, 2012, 4:56 PM
    Watson Pharmaceuticals (WPI) confirms it will buy Actavis Group for at least €4.25B euros ($5.60B), in a deal that cements its status as one of the world's biggest suppliers of generic drugs. WPI +5.5% AH.
    | Comment!
  • Apr. 23, 2012, 4:03 PM
    Watson Pharmaceuticals (WPI +0.1%) is close to announcing a $5.6B deal for Actavis by Wednesday, according to sources. The deal is an important one for Deutsche Bank (DB -3.6%), which was left holding billions of euros of Actavis debt after a leveraged buyout in 2007.
    | Comment!
  • Apr. 18, 2012, 2:56 PM
    Valeant Pharmaceuticals (VRX +0.1%) and DepoMed (DEPO +3.0%) sue Watson Pharmaceuticals (WPI +0.2%) over its generic glumetza diabetes drug, according to reports. Sales of Glumetza are tipped to reach more than $100M this year.
    | Comment!
  • Apr. 13, 2012, 10:58 AM
    Watson Pharmaceuticals (WPI +0.1%) sees bank line up to help finance the firm's $6B takeover of Actavis. Source say the initial structure of a proposed agreement is for a $2B term loan and a $4B bridge loan, with BoA the frontrunner to lead the deal.
    | Comment!
  • Apr. 11, 2012, 12:23 PM
    Watson Pharmaceuticals (WPI +1.3%) is on track to announce a deal to buy Swiss-based Actavis for ~$6B by the end of April, creating one of the world's biggest producers of generic drugs, Reuters reports. Watson believes a move would help it compete more effectively against rivals like Teva and Novartis unit Sandoz.
    | Comment!
  • Apr. 10, 2012, 8:17 AM
    Watson Pharmaceuticals (WPI) receives FDA approval for a generic version of Vancocin and plans to begin shipping the products immediately.
    | Comment!
  • Mar. 21, 2012, 11:45 AM
    Watson Pharmaceuticals (WPI +0.8%) bounces around violently after word leaks that the company is close to signing off on a deal to buy Icelandic firm Actavis for €5B-€5.5B. Shares dropped sharply off the news, then reversed themselves in a slingshot move higher, and now stand +0.6%.
    | Comment!
  • Mar. 15, 2012, 2:58 PM
    Mylan (MYL +1.4%) has pulled out of discussions to buy a stake in Italian pharmaceutical firm Rottapharm after the selling family wouldn't agree to give up control, nor compromise enough on price. Rottapharm has also held talks with Watson Pharmaceuticals (WPI -0.2%) and Forest Labs (FRX +0.1%), however Watson doesn't appear likely to be a buyer.
    | Comment!
  • Mar. 2, 2012, 10:36 AM
    Watson Pharmaceuticals (WPI -0.3%) confirms that it launched a generic version of Prometrium as part of an agreement with Abbott Laboratories (ABT +0.1%). Over the last 12-month reporting period, Prometrium had sales of close to $198M.
    | Comment!
  • Feb. 27, 2012, 7:21 AM
    Watson Pharmaceutical (WPI) confirms that it received a complete response letter from the FDA spelling out concerns over its progesterone vaginal gel designed to reduce the risk of preterm births. The letter states that the treatment doesn't meet the level of statistical significance expected to support the approval of a product from a single trial.
    | Comment!
  • Feb. 14, 2012, 9:02 AM
    More on Watson (WPI +2.2%) Q4: Net income more than quintuples to $94.8M, with earnings boosted by generic versions of Pfizer's Lipitor cholesterol treatment and J&J's Concerta ADHD drug. Watson ups its 2012 EPS guidance to $5.50-$5.80 from $5.25-$5.55 and vs. $5.60 consensus. Also ups rev forecast by $100M to $5.4B.
    | Comment!
  • Feb. 14, 2012, 7:19 AM
    Watson Pharmaceuticals (WPI): Q4 EPS of $1.77 beats by $0.02. Revenue of $1.55B (+81.5% Y/Y) in-line. (PR)
    | Comment!
  • Feb. 14, 2012, 12:05 AM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
  • Feb. 13, 2012, 5:30 PM
    Notable earnings before Tuesday's open: AVP, BWA, FOSL, GT, HCP, HSP, HST, KORS, MMC, OMC, TRP, UTHR, VAL, WPI
    | Comment!
Visit Seeking Alpha's
ACT vs. ETF Alternatives
Company Description
Actavis PLC specialty pharmaceutical company engaged in developing, manufacturing and distributing generic, brand and biosimilar products.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States